SGO on Twitter: "Olaparib maintenance therapy improves overall survival in recurrent #ovariancancer - important update of the SOLO2 trial at #ASCO20 #SGOatASCO #gyncsm https://t.co/xX2D6nyErE" / Twitter
3 Charts | Olaparib: A New Hope for BRCA Patients with Ovarian Cancer
Olaparib maintenance therapy in platinum-sensitive relapsed ovarian... | Download Scientific Diagram
Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy - European Journal of Cancer
Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial - The Lancet Oncology
SOLO-1 Phase III trial demonstrates Lynparza maintenance therapy cut risk of disease progression or death by 70% in patients with newly-diagnosed, advanced BRCA-mutated ovarian cancer - AstraZeneca
LYNPARZA® (olaparib) Efficacy for gBRCAm, HER2-negative Metastatic Breast Cancer
Efficacy of LYNPARZA® (olaparib) for Maintenance in Recurrent Ovarian Cancer
SOLO-2: Overall Survival Data on Olaparib for Relapsed, BRCA-Mutated Ovarian Cancer
Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer - Annals of Oncology
Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer - Annals of Oncology
PARP inhibitors in ovarian cancer - Cancer Treatment Reviews
Efficacy of LYNPARZA® (olaparib) from Study 19
PARP inhibitor (olaparib) dramaticalyl extends progression free survival in 1L Maintenance BRCAm ovarian cancer data. Hazard ratio = 0.30. : r/medicine
Olaparib Maintenance Reduces the Risk of Recurrence in Newly
Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy | British Journal of Cancer
VisualAbstract: Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer | 2 Minute Medicine
LYNPARZA® (olaparib) First-Line Maintenance Therapy Nearly Doubled the Time Without Disease Progression or Death in Phase 3 POLO Trial for Patients with Germline BRCA-Mutated Metastatic Pancreatic Cancer | BioSpace
Use of PARP inhibitors in ovarian cancer | Cancer World Archive
Olaparib Maintenance Therapy Delays Ovarian Cancer Progression - NCI
Olaparib maintenance confers durable PFS benefit in advanced BRCA -mutated ovarian cancer
Final Overall Survival Analysis From SOLO2 in Ovarian Cancer - The ASCO Post
Predictors of progression free survival, overall survival and early cessation of chemotherapy in women with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) starting third or subsequent line(≥3) chemotherapy – The GCIG
Olaparib for Metastatic Castration-Resistant Prostate Cancer | NEJM
Use of PARP inhibitors in ovarian cancer | Cancer World Archive
Olaparib for Metastatic Breast Cancer | NEJM Resident 360 <meta property="twitter:image" content="https://resident360files.nejm.org/image/upload/c_fit,f_auto,h_120,w_120/v1538599218/u8buf4o8mgdxgmfcczjk.png" /> <meta property="og:image" content="https ...
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial - The Lancet Oncology
